ISELIN, N.J., Nov 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Study did not achieve statistical significance Pharmos Corporation (Nasdaq: PARS) today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine. The multi-center, randomized...  

Iselin, NJ, November 6, 2008 - Pharmos Corporation (Nasdaq: PARS) today reported results for the third quarter ended September 30, 2008. The Company recorded a net loss of $2.8 million, or $0.11 per share, for the third quarter 2008 compared to a net loss of $3.5 million, or $0.14 per share, in the third quarter 2007. Cash and cash equiva...  

ISELIN, N.J., Aug 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today announced that effective October 31, 2008 it will cease operations in Rehovot, Israel, and manage those activities currently based in Rehovot out of the Company's US headquarters in Iselin, New Jersey. The research programs in I...  

Iselin, N.J., May 14, 2008 — Pharmos Corporation (Nasdaq: PARS) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 5:15 PM Central Europe Daylight Time (GMT +2:00, or 11:15 AM Eastern Day...  

Iselin, NJ, February 28, 2008 - Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve-month period and ended December 31, 2007.

Fourth Quarter Ended December 31, 2007
For the fourth quarter ended December 31, 2007, Pharmos reported a net loss of $2.7 million, or $0.11 per...  

Iselin, NJ, January 3, 2008 - Pharmos Corporation (Nasdaq: PARS) announced today certain changes in its Board of Directors and Management, effective immediately.

Board Changes
Robert F. Johnston has been elected to the Board as Executive Chairman.

Haim Aviv, Ph.D., David Schlachet and Mo...  

ISELIN, N.J., Dec 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that President & COO Alan Rubino has elected to resign from the Company. Mr. Rubino joined Pharmos in November 2005 and was instrumental in the strategic acquisition and the subsequent integration of Vela Pharmaceutica...  

ISELIN, N.J., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that its Chief Executive Officer, Elkan Gamzu, Ph.D., will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Monday, November 5, 2007 at 10:55 AM Eastern Time. The conference is taking place...  

ISELIN, N.J., Oct 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today it is undertaking a second phase of restructuring as it continues to optimize the balance between cash resources and its most promising scientific research and development programs. This second phase involves a workforce r...  

ISELIN, N.J., Sept 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today it has issued the below Letter to Shareholders as part of its proxy materials for its annual meeting scheduled for October 24, 2007. Pharmos is among the first corporate issuers able to take advantage of the recently enac...